• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • PROs
    • Menopause Rating Scale
      • Menopause Rating Scale (MRS) – Languages
    • Aging Male Symptoms Scale
      • AMS – properties as an outcome measure
      • AMS – properties as a screening tool
    • Quality of Sexual Function Scale
      • Quality of Sexual Function Scale
    • Short Term Hormone Effect Scale
      • Short Term Hormone Effect Scale
    • Research team
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Study Type: Real-World Evidence

Kossack Nils, Schoenfelder T., Schultze Michael, Pignot Marc, Mehta S., Nazareth T., Walzer S., Real-World Cost Difference in Patients With Psoriasis Initiating Apremilast vs. Secukinumab After Conventional Systemic Therapy Using German Sickness Fund Data DDK KOMPAKT 2020. JDDG Volume 18 Issue S1. 2020. 2020; 10.1111/ddg.14021.
Vogelmeier Claus F., Pignot Marc, Wiklund F., Nuevo J., Telg G., Janson C., Risk of future exacerbations among COPD patients – a real-world register-based cohort study (AvoidEx). European Respiratory Journal. 2020; 10.1183/13993003.
Vogelmeier Claus F., Nuevo J., Telg G., Friedrich Felix W., Pignot Marc, Wiklund F., Janson C., Real-Life Treatment Patterns and Burden of Disease Among Patients with COPD - A Large Observational Study. American Journal of Respiratory and Critical Care Medicine. 2020; 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3331.
O'Kelly James, Bartsch Robert, Kossack Nils, Borchert Julia, Pignot Marc, Hadji Peyman, Real-World Effectiveness of Osteoporosis Treatments in Germany Value in Health, Volume 23. 2020; S592. 10.1016/j.jval.2020.08.1134.
Birkeland Kåre I., Bodegard Johan, Eriksson Jan W., Norhammar Anna, Haller Hermann, Linssen Gerard C. M., Banerjee Amitava, Thuresson Marcus, Okami Suguru, Garal-Pantaler Elena, Overbeek Jetty, Mamza Jil Billy, Zhang Ruiqi, Yajima Toshitaka, Komuro Issei, Kadowaki Takashi, Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes Obes Metab.. 2020; 22:1607–1618. 10.1111/dom.14074.
Hilz M., Das Mahapatra P., Fan Q., Marczykowski F., Werner B., Pignot Marc, Bender J., Punekar R., Hamed A., Edigkaufer M., Evaluation of Treatment Patterns of Fabry Disease Utilizing Medical Claims Analyses of a German Sickness Fund Database Value in Health, VOLUME 23. 2020; SUPPLEMENT 1, S347. 10.1016/j.jval.2020.04.1321.
Kossack Nils, Schoenfelder T., Schultze Michael, Pignot Marc, Mehta S., Nazareth T., Walzer S., Real-World Cost Difference in Patients with Psoriasis Newly Initiating Apremilast vs. Biologic Treatment after Conventional Systemic Therapy: A Retrospective Analysis of German Sickness Fund Data. Value in Health (22). 2019; 10.1016/j.jval.2019.09.2645.
Birkeland Kåre I., Bodegard Johan, Eriksson Jan W., Norhammar Anna, Thuresson Marcus, Pignot Marc, Garal-Pantaler Elena, Yajima Toshitaka, Komuro Issei, Kadowaki Takashi, Cardiorenal disease is the most common first CV manifestation in type 2 diabetes and associated with increased mortality: a large multinational observational study EASD Congress. 2019;
Birkeland Kåre I., Bodegard Johan, Eriksson Jan W., Norhammar Anna, Thuresson Marcus, Pignot Marc, Garal-Pantaler Elena, Yajima Toshitaka, Komuro Issei, Kadowaki Takashi, Cardiorenal disease is the most common first CV manifestation in type 2 diabetes and associated with increased mortality: a large multinational observational study European Association for the Study of Diabetes 55th Annual Meeting. 2019;
Birkeland Kåre I., Bodegard Johan, Norhammar Anna, Kuiper JG, Georgiado E., Beekman- Hendriks WL, Thuresson Marcus, Pignot Marc, Herings RMC, Kooy A., How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes Metab. 2019; 10.1111/dom.13612.
Kraus MR, Kleine H., Thönnes S., Pignot Marc, Sanchez Gonzalez Y., Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data. Infect Dis Ther.. 2018; 7(3):339-352. 10.1007/s40121-018-0205-2.
Kraus MR, Kleine H., Thönnes S., Pignot Marc, Sanchez Gonzalez Y., Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data. Infect Dis Ther. 2018; Sep;7(3):327-338. 10.1007/s40121-018-0204-3.
  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Go to Next Page »

sidebar

Search our Publications

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2025 ZEG Berlin

Impressum

Website by Laura Yeffeth.